STAT+: Sanofi MS drug gets positive review in Europe following FDA

STAT PlusNewsletterThe Readout Sanofi MS drug gets positive review in Europe following FDA Plus other biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanApril 24, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Regeneron is in the headlines again: It cut a pricing deal with the Trump administration and won approval for a hearing loss gene therapy. Also, Medicare and the FDA are getting creative with their efforts to speed medical device coverage. And since it’s totally worth it, sign up for STAT+ between now and Saturday and you’ll get 60% off your first year.Advertisement MS drug rejected by FDA gets warmer reception in Europe From STAT’s Andrew Joseph: A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer audience in European regulators, who recommended today that the medicine should be approved. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, drug pricing, Pharmaceuticals, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech April 24, 2026 STAT Plus: FDA to speed up review of three psychedelics as mental health treatments Biotech April 23, 2026 STAT Plus: Trump celebrates closing first round of drug pricing deals, promises more ahead Advertisement The Readout April 23, 2026 STAT Plus: Sanofi research priorities in flux as new CEO logs in D.C. Diagnosis April 23, 2026 STAT Plus: RFK Jr. backs off some MAHA issues Adam's Biotech Scorecard April 23, 2026 STAT Plus: Can Erasca be biotech’s next big thing? We’ll see Subscriber Picks